Canada markets closed
LATEST UPDATE

NO WEEKLY BRIEF NEWSLETTER FOR THE WEEKEND OF OCT. 16-17

We are taking a short break, but we will be back next week. Stay tuned!

Certara, Inc. (CERT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
37.84+0.09 (+0.24%)
At close: 4:00PM EDT
37.84 0.00 (0.00%)
After hours: 04:05PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close37.75
Open37.38
Bid37.50 x 1000
Ask39.00 x 800
Day's Range36.79 - 38.50
52 Week Range23.75 - 41.79
Volume469,070
Avg. Volume917,207
Market Cap5.955B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.39
Earnings DateAug. 05, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.75
  • GlobeNewswire

    Certara Appoints Patrick F. Smith to President of Integrated Drug Development

    PRINCETON, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Patrick F. Smith, Pharm.D. as president of Integrated Drug Development (IDD), reporting to CEO William F. Feehery. Dr. Smith will lead the Company’s global drug development services team, which creates value for clients across the entire drug development life cycle using biosimulation and quantitative approaches. Dr. Smith succeeds Craig R. Rayner,

  • GlobeNewswire

    Certara Appoints Drayton T. Virkler as Chief Commercial Officer

    Experienced commercial leader brings 20 years of experience in pharmaPRINCETON, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Drayton T. Virkler to the newly created position of Chief Commercial Officer. In this role, Mr. Virkler will drive the Company’s global commercial strategy and execution and expand the business development team. “I am pleased to welcome Drayton as our new Chief Commercial Officer,

  • GlobeNewswire

    Certara Completes Acquisition of Pinnacle 21

    Complementary technologies accelerate and help assure success in the drug development processPRINCETON, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the completion of the previously announced transaction to acquire Pinnacle 21, a leading provider of SaaS solutions for clinical data fitness, regulatory compliance and submission readiness. At closing, equity holders of Pinnacle 21 received approximately $250 million in cash